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Simple Summary: Although anti-angiogenetic agents (AAA) are mainstay treatments for clear cell
renal cell carcinoma (ccRCC), there are very few histology-based predictive biomarkers applicable in
routine clinical practice. Considering that frameshifts contribute to antitumor immunity and ccRCC
harbors the highest indel proportion across tumors, we hypothesized that protein markers frequently
mutated via frameshift indels could predict prognosis and response to AAA. We evaluated the
prognostic impact of the individual protein markers and found five proteins showing independent
prognostic value. Utilizing the five proteins, we developed an integrated biomarker—Neo-fs index.
High Neo-fs index predicted better prognosis and AAA response. High Neo-fs index, which harbored
greater single nucleotide variant and indel mutation, was also associated with antitumor immune
gene signature. Neo-fs index could be a practical biomarker to improve risk stratification and predict
AAA response in ccRCC patients.
Abstract: Background: Frameshift indels have emerged as a predictor of immunotherapy response
but were not evaluated yet to predict anti-angiogenetic agent (AAA) response or prognosis in
clear cell renal cell carcinoma (ccRCC). Methods: Here, to develop biomarkers that predict survival
and response to AAA, we evaluated the immunohistochemical expression of proteins whose genes
frequently harbor frameshift indels in 638 ccRCC patients and correlated the individual and integrated
markers with prognosis and AAA response. The mutational landscape was evaluated using targeted
next-generation sequencing in 12 patients concerning protein markers. Immune gene signatures
were retrieved from TCGA RNA seq data. Results: Five proteins (APC, NOTCH1, ARID1A, EYS,
and filamin A) were independent adverse prognosticators and were incorporated into the Neo-fs
index. Better overall, disease-specific and recurrence-free survival were observed with high Neo-
fs index in univariate and multivariate survival analyses. Better AAA responses were observed
with a high Neo-fs index, which reflected increased MHC class I, CD8+ T cell, cytolytic activity,
and plasmacytoid dendritic cell signatures and decreased type II-IFN response signatures, as well
as greater single-nucleotide variant (SNV) and indel counts. Conclusions: Neo-fs index, reflecting
antitumor immune signature and more SNVs. and indels, is a powerful predictor of survival and
AAA response in ccRCC.
Keywords: clear cell renal cell carcinoma; frameshift insertion and deletion; immunohistochemical
biomarker; anti-angiogenic agent response; prognosis
1. Introduction
Frameshift insertions and deletions (indels) have gained considerable attention owing
to the fact that numerous neoantigens with high specificity for the major histocompati-
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bility complex (MHC) are produced upon the accumulation of such mutations, thereby
contributing to antitumor immunity [1]. In particular, clear cell renal cell carcinoma (RCC),
accounting for 65-70% of all renal malignancies [2], harbors the highest proportion of
coding indels across all tumor types; this phenomenon accounts for its immunogenicity
and a high response to immunotherapy despite low non-synonymous single-nucleotide
variant (SNV) burden [1]. Although frameshift indels first gained attention as a predictor of
immune checkpoint inhibitor (ICI) response, a high load of frameshift indels also correlated
with improved survival in ICI-naïve NSCLC patients [1], thereby suggesting extended
applicability to the prediction of the response to therapeutic agents beyond ICIs as well as
the prognosis.
Anti-angiogenetic agents (AAAs), including multi-targeted tyrosine kinase inhibitors
(e.g., sunitinib, pazopanib, sorafenib, and axitinib) and VEGF-A monoclonal antibody
(e.g., bevacizumab) [3], constitute a mainstay of treatment for advanced RCC patients [4].
With the recent incorporation of ICIs into a first-line systematic treatment of advanced
RCC [5–7], biomarkers to predict AAA response have become more crucial for optimizing
the treatment choice.
Turajlic et al. [1] have identified particular genes that are frequently mutated via
frameshift indels and produce multiple high-affinity neoantigens in a pan-cancer analysis.
We have hypothesized that analyzing the expression of these gene products, which might be
reflective of frameshift indel burden, would affect prognosis and treatment response in clear
cell RCC. Therefore, we investigated the proteins coded by genes that frequently harbor
frameshift indels, resulting in the production of numerous neoantigens, and correlated
them with prognosis as well as therapeutic responses to AAAs and immunotherapy in clear
cell RCC patients in an attempt to develop novel prognostic and predictive biomarkers.
2. Results
2.1. Baseline Characteristics of the Study Population
The clinicopathological characteristics of the patients with clear cell RCC are depicted
in Table 1. The mean age was 55.7 ± 12.0 years (median 56; range, 23–86) with a male
to female ratio of 3.0. Partial nephrectomy was conducted in 340 (53.3%) patients and
radical nephrectomy in 298 (46.7%) cases. The mean tumor size was 4.3 ± 2.8 cm (median
3.5; range, 0.3–21.0). Upon using the American Joint Committee on Cancer (AJCC) cancer
staging system, the clear cell RCC population was found to consist of 473 patients with pT1
(74.1%), 23 patients with pT2 (3.6%), 136 patients with pT3 (21.3%), and six patients with
pT4 disease (0.9%). Lymph node metastasis (pN1) was identified in 15 (2.4%) patients, and
synchronous distant metastasis was present in 38 (6.0%) patients. The median follow-up
duration was 70 months (range, 1-98). With respect to adjuvant therapy, 65 (10.2%) patients
received AAAs (sunitinib for 30 patients, pazopanib for 31 patients, and sorafenib for four
patients as first-line), 38 (6.0%) patients received mammalian target of rapamycin (mTOR)
inhibitors (everolimus for 35 patients and temsirolimus for three patients).
Table 1. Clinicopathological characteristics of the study population and immunohistochemistry results.
Clinicopathological Characteristics N (%) Immunohistochemistry N (%)
Sex APC (0–1 vs. 2–3)
Male 480 (75.2%) Low expression 548 (86.7%)
Female 158 (24.8%) High expression 84 (13.3%)
Age (years) NOTCH1 (0–1 vs.2–3)
<55 years 316 (49.5%) Low expression 436 (69.0%)
≥55 years 322 (50.5%) High expression 196 (31.0%)
Procedure ARID1A (0–2 vs. 3)
Partial nephrectomy 340 (53.3%) Low expression 627 (99.1%)
Radical nephrectomy 298 (46.7%) High expression 6 (0.9%)
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Table 1. Cont.
Clinicopathological Characteristics N (%) Immunohistochemistry N (%)
WHO/ISUP nuclear grade * FAT1 (0–1 vs. 2–3)
1-2 331 (51.9%) Low expression 474 (74.9%)
3-4 307 (48.1%) High expression 159 (25.1%)
Tumor size (cm) VHL (0 vs. 1–3)
<4 cm 388 (60.8%) Low expression 177 (28.0%)
≥4 cm 250 (39.2%) High expression 455 (72.0%)
pT stage EYS (0–1 vs. 2–3)
pT1-2 496 (77.7%) Low expression 527 (83.0%)
pT3-4 142 (22.3%) High expression 108 (17.0%)
pN stage KMT2D (0–1 vs. 2–3)
pN0/pNx 623 (97.6%) Low expression 296 (46.8%)
pN1 15 (2.4%) High expression 337 (53.2%)
Lymphovascular invasion Filamin A (0–2 vs. 3)
Absent 537 (84.2%) Low expression 579 (91.5%)
Present 101 (15.8%) High expression 54 (8.5%)
Resection margin PTEN (0 vs. 1–3)
Clear 624 (97.8%) Low expression 112 (17.6%)
Involved 14 (2.2%) High expression 526 (82.4%)
Necrosis p53 (0 vs. 1–3)
Absent 538 (84.3%) Low expression 36 (5.6%)





Not received 573 (89.8%)
Received 65 (10.2%)
mTOR inhibitor
Not received 600 (94.0%)
Received 38 (6.0%)
* WHO/International Society of Urological Pathology (ISUP) Grade 1, 28 cases; grade 2, 303 cases; grade 3, 245 cases; grade 4, 62 cases. Of
the 638 samples, six samples lacked sufficient tumor cells for testing the expression of APC, NOTCH1, and VHL; five lacked sufficient
tumor cells for testing the expression of ARID1A, FAT1, KMT2D, and Filamin A; three lacked sufficient tumor cells for testing the expression
of EYS.
2.2. Immunohistochemical Marker Expression
The results of immunohistochemical marker expression, including the number and
percentage of patients for each marker, are shown in Table 1.
2.3. Prognostic Impact of Immunohistochemical Markers
Univariate Cox regression analysis revealed that high expression of five markers—of
the ten markers evaluated—including APC, NOTCH1, ARID1A, EYS, and filamin A, was
associated with adverse prognosis (Table 2). Further, expression of four other markers,
including FAT1, VHL, PTEN, and p53, were found to be associated with favorable prognosis
in univariate Cox regression (Table 2); KMT2D did not show any prognostic significance
(Table 2). In the AAA-recipient subgroup, expression of ARID1A was associated with
shorter overall survival (OS) (hazard ratio (HR) 10.061; p = 0.033) and disease-specific
survival (DSS) (HR 10.061; p = 0.033) (Table S1). In the AAA-recipient subgroup, EYS
expression was also associated with shorter OS (HR 2.718; p = 0.002), DSS (HR 2.718;
p = 0.002), and recurrence-free survival (RFS) (HR 2.848; p = 0.016) (Table S1).
Clinicopathological variables that were found to be significantly related to survival
in univariate Cox regression were adjusted for in the multivariate Cox regression. Five
markers (APC, NOTCH1, ARID1A, EYS, and filamin A) were found to be independent and
significant predictors of poor survival when highly expressed (Table 3). High expression
of APC (HR 2.717; p = 0.006) and Filamin A (HR 2.108; p = 0.048) was an independent
prognostic factor for DSS. High NOTCH1 expression demonstrated independent prognostic
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significance for OS (HR 1.694; p = 0.028) and RFS (HR 2.021; p = 0.020). Tumors with high
ARID1A expression showed adverse OS (HR 4.558; p = 0.005) and DSS (HR 6.303; p = 0.005).
High EYS expression was also an independent prognostic factor for adverse OS (HR
1.806; p= 0.018) and DSS (HR 2.212; p = 0.012). Meanwhile, PTEN and p53 expression did
not reveal independent prognostic significance (Table 3). In an AAA-recipient subgroup,
ARID1A and EYS retained independent prognostic significance for adverse OS (ARID1A,
HR 9.835, p = 0.041; EYS, HR 2.433; p = 0.009) and DSS (ARID1A, HR 9.835, p = 0.041; EYS,
HR 2.433; p = 0.009) (Table S2).
Table 2. Univariate analysis to identify a correlation between survival and clinicopathological factors and immunohisto-
chemical results in patients receiving anti-angiogenic therapies.
Variables
Overall Survival Disease-Specific Survival Recurrence-Free Survival
HR (95% CI) p HR (95% CI) p HR (95% CI) p
Clinicopathologic
variables
Female (vs. Male) 0.729 (0.430–1.238) 0.242 0.726 (0.376–1.402) 0.341 0.800 (0.422–1.515) 0.493
Age ≥ 55 years 3.328 (2.057–5.387) <0.001 2.702 (1.516–4.817) 0.001 2.316 (1.322–4.059) 0.003
Radical nephrectomy (vs.
partial nephrectomy) 3.797 (2.345–6.146) <0.001 16.769 (6.069–46.335) <0.001 3.915 (2.167–7.073) <0.001
ISUP grade 3–4 4.052 (2.464–6.663) <0.001 12.064 (4.818–30.210) <0.001 5.385 (2.785–10.414) <0.001
Tumor size ≥ 4 cm 5.622 (3.474–9.097) <0.001 19.062 (7.610–47.747) <0.001 4.818 (2.724–8.520) <0.001
pT3–4 6.281 (4.117–9.584) <0.001 16.709 (8.807–31.699) <0.001 8.920 (5.205–15.289) <0.001
pN1 (vs. pN0/pNx) 15.837 (8.688–28.868) <0.001 26.214 (13.893–49.463) <0.001 69.925 (25.878–188.944) <0.001
Lymphovascular
invasion 7.281 (4.777–11.097) <0.001 12.505 (7.250–21.569) <0.001 6.041 (3.522–10.360) <0.001
Margin involvement 5.792 (2.793–12.010) <0.001 7.757 (3.511–17.136) <0.001 9.450 (4.038–22.113) <0.001
Necrosis 7.462 (4.926–11.304) <0.001 23.111 (12.436–42.951) <0.001 8.777 (5.172–14.893) <0.001
Sarcomatoid change 7.289 (4.416–12.031) <0.001 12.974 (7.516–22.396) <0.001 9.280 (4.792–17.970) <0.001
AAA recipient 11.146 (7.334–16.938) <0.001 36.948 (20.155–67.735) <0.001 56.860 (32.589–99.207) <0.001
mTOR inhibitor recipient 13.798 (8.881–21.438) <0.001 32.525 (19.109–55.362) <0.001 46.282 (24.568–87.191) <0.001
Immunohistochemistry
High APC expression 1.663 (0.979–2.827) 0.060 2.129 (1.143–3.966) 0.017 1.537 (0.774–3.049) 0.219
High NOTCH1
expression 1.806 (1.182–2.758) 0.006 2.029 (1.195–3.447) 0.009 1.835 (1.077–3.128) 0.026
High ARID1A expression 4.634 (1.675–12.820) 0.003 6.290 (1.954–20.251) 0.002 2.307 (0.319–16.687) 0.408
High FAT1 expression 0.659 (0.383–1.134) 0.132 0.415 (0.188–0.916) 0.029 0.627 (0.315–1.245) 0.182
High VHL expression 0.573 (0.375–0.877) 0.010 0.482 (0.286–0.814) 0.006 0.527 (0.307–0.904) 0.020
High EYS expression 2.416 (1.540–3.789) <0.001 3.294 (1.911–5.676) <0.001 1.710 (0.919–3.180) 0.090
High KMT2D expression 0.859 (0.562–1.313) 0.483 0.967 (0.566–1.653) 0.904 0.705 (0.413–1.205) 0.201
High Filamin A
expression 2.439 (1.417–4.198) 0.001 3.826 (2.080–7.040) <0.001 3.217 (1.659–6.236) 0.001
High PTEN expression 0.438 (0.280–0.686) <0.001 0.284 (0.167–0.482) <0.001 0.637 (0.337–1.207) 0.167
High p53 expression 0.719 (0.329–1.570) 0.408 0.387 (0.176–0.854) 0.019 0.361 (0.164–0.798) 0.012
Neo-fs index
0–1 4.497 (1.759–11.498) 0.002 8.655 (3.206–23.369) <0.001 4.715 (1.418–15.679) 0.011
2 2.811 (1.388–5.694) 0.004 4.553 (1.978–10.478) <0.001 2.797 (1.143–6.843) 0.024
3 2.424 (1.337–4.395) 0.004 2.496 (1.085–5.741) 0.031 1.647 (0.710–3.822) 0.246
4 1.673 (0.981–2.853) 0.059 2.392 (1.220–4.691) 0.011 1.804 (0.946–3.439) 0.073
5 (reference) 1 - 1 - 1 -
p-for trend 0.690 (0.584–0.815) <0.001 0.608 (0.499–0.741) <0.001 0.711 (0.573–0.883) 0.002
Neo-fs index
Low (≤4) 1 - 1 - 1 -
High (>4) 0.461 (0.301–0.708) <0.001 0.331 (0.188–0.581) <0.001 0.495 (0.291–0.844) 0.010
Neo-fs index: The number of markers with low expression among the five independent prognosticators (APC, NOTCH1, ARID1A,
EYS, and Filamin A); The number of patients with the Neo-fs index 0–1, 2, 3, 4, and 5 was 12, 39, 71, 140, and 369, respectively. AAA,
anti-angiogenetic agent; mTOR inhibitor, mammalian target of rapamycin (mTOR) inhibitor; CI, confidence interval.
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2.4. Prognostic Impact of Neo-Fs Index and its Association with Clinicopathological Characteristics
In the survival analysis, we identified five independent prognostic markers—out of
ten immunohistochemical markers—whose genes are susceptible to the incorporation of
frameshift indels, thereby resulting in the production of numerous immunogenic neoanti-
gens [1]. Considering that loss-of-function frameshift indels result in loss of corresponding
protein expression, we hypothesized that an increased number of protein markers with
low expression might exert a cumulative effect on survival. We created the Neo-fs index—
defined as the number of marker proteins with low expression among the five independent
prognosticators (APC, NOTCH1, ARID1A, EYS, and filamin A)—to develop a simple, prac-
tical biomarker with potential prognostic or predictive value reflective of tumor biology.
Table 3. Multivariate analysis to identify a correlation between survival and clinicopathological factors and immunohisto-
chemical results in patients receiving anti-angiogenic therapies.
Variables
Overall Survival (OS) Disease-Specific Survival(DSS)
Recurrence-Free Survival
(RFS)
HR (95% CI) p HR (95% CI) p HR (95% CI) p
Clinicopathologic variables
Age ≥ 55 years 3.005 (1.833–4.925) <0.001 2.501 (1.365–4.585) 0.003 1.671 (0.923–3.027) 0.090
Radical nephrectomy (vs.
partial nephrectomy) 0.915 (0.484–1.729) 0.784 1.919 (0.593–6.207) 0.276 0.811 (0.394–1.671) 0.571
ISUP grade 3–4 1.271 (0.704–2.296) 0.426 1.799 (0.634–5.105) 0.269 2.396 (1.098–5.227) 0.028
Tumor size ≥ 4 cm 2.374 (1.220–4.620) 0.011 3.516 (1.160–10.653) 0.026 2.348 (1.056–5.220) 0.036
pT3–4 0.874 (0.442–1.729) 0.699 0.824 (0.321–2.116) 0.687 1.545 (0.707–3.379) 0.276
pN1 (vs. pN0/pNx) 1.270 (0.585–2.757) 0.546 1.112 (0.503–2.458) 0.792 3.916 (1.075–14.266) 0.038
Lymphovascular invasion 1.537 (0.657–3.593) 0.322 1.409 (0.561–3.537) 0.465 2.162 (1.101–4.245) 0.025
Margin involvement 2.552 (1.441–4.519) 0.001 2.527 (1.222–5.225) 0.012 3.193 (1.033–9.870) 0.044
Necrosis 1.633 (0.885–3.012) 0.116 2.186 (0.948–5.038) 0.066 1.386 (0.642–2.994) 0.406
Sarcomatoid change 1.311 (0.710–2.420) 0.387 1.396 (0.739–2.636) 0.304 0.912 (0.392–2.122) 0.830
AAA recipient 2.796 (1.342–5.825) 0.006 6.642 (2.642–16.699) <0.001 29.152(13.253–64.125) <0.001
mTOR inhibitor recipient 1.429 (0.696–2.934) 0.330 1.219 (0.586–2.537) 0.596 1.176 (0.540–2.562) 0.683
Immunohistochemistry
High APC expression NA NA 2.717 (1.333–5.539) 0.006 NA NA
High NOTCH1 expression 1.694 (1.057–2.714) 0.028 1.782 (0.963–3.298) 0.066 2.021 (1.116–3.659) 0.020
High ARID1A expression 4.558 (1.568–13.252) 0.005 6.303 (1.726–23.016) 0.005 NA NA
High FAT1 expression 1.231 (0.690–2.197) 0.483 1.287 (0.542–3.053) 0.567 NA NA
High VHL expression 1.131 (0.712–1.797) 0.601 1.273 (0.712–2.276) 0.415 1.003 (0.558–1.801) 0.992
High EYS expression 1.806 (1.108–2.945) 0.018 2.212 (1.188–4.119) 0.012 NA NA
High Filamin A expression 1.524 (0.795–2.920) 0.204 2.108 (1.007–4.415) 0.048 1.243 (0.497–3.112) 0.642
High PTEN expression 0.977 (0.602–1.585) 0.924 0.999 (0.562–1.775) 0.998 NA NA
High p53 expression NA NA 0.745 (0.325–1.707) 0.486 0.930 (0.364–2.377) 0.880
Neo-fs index
0–1 2.099 (0.775–5.688) 0.145 3.135 (1.029–9.556) 0.044 1.840 (0.454–7.457) 0.393
2 2.285 (1.011–5.162) 0.047 4.494 (1.578–12.800) 0.005 2.935 (1.038–8.296) 0.042
3 2.774 (1.486–5.177) 0.001 3.007 (1.238–7.300) 0.015 1.475 (0.564–3.86) 0.428
4 1.128 (0.628–2.025) 0.688 1.665 (0.749–3.699) 0.211 2.265 (1.105–4.642) 0.026
5 (reference) 1 - 1 - 1 -
p-for trend 0.757 (0.632–0.907) 0.003 0.690 (0.552–0.863) 0.001 0.787 (0.615–1.007) 0.057
Neo-fs index
Low (≤4) 1 - 1 - 1 -
High (>4) 0.595 (0.372–0.951) 0.030 0.430 (0.225–0.825) 0.011 0.480 (0.259–0.890) 0.020
Neo-fs index: The number of markers with low expression among the five independent prognosticators (APC, NOTCH1, ARID1A,
EYS, and Filamin A); The number of patients with the Neo-fs index 0–1, 2, 3, 4, and 5 was 12, 39, 71, 140, and 369, respectively. AAA,
anti-angiogenetic agent; mTOR inhibitor, mammalian target of rapamycin (mTOR) inhibitor; CI, confidence interval.
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Univariate Cox regression analysis revealed a gradual improvement in OS (p-for-trend
< 0.001), DSS (p-for-trend < 0.001), and RFS (p-for-trend = 0.002) with higher Neo-fs index
values (increased in a stepwise manner) (Table 2). Multivariate Cox regression revealed
that the cumulative effect of high Neo-fs index values on favorable OS (p-for trend = 0.003)
and DSS (p-for trend = 0.001) was retained (Table 3). The Kaplan-Meier curve also revealed
a gradual increase in OS (log-rank p < 0.001), DSS (log-rank p < 0.001), and RFS (log-rank
p = 0.018) with higher values of the Neo-fs index (Figure 1). In the AAA-recipient subgroup,
the cumulative effect higher Neo-fs index values on favorable survival was retained in
univariate (OS, p-for trend = 0.004; DSS, p-for trend = 0.004; RFS, p-for trend = 0.022) and
multivariate (OS, p-for trend = 0.001; DSS, p-for trend = 0.001) Cox regression analyses
(Tables S1 and S2).
We next stratified the patients based on the Neo-fs index (low ≤4 vs. high >4) and
revealed that high Neo-fs index was associated with longer OS (HR 0.461; p < 0.001; log-
rank p < 0.001], DSS (HR 0.331; p < 0.001; log-rank p < 0.001] and RFS (HR 0.495; p = 0.010;
log-rank p = 0.008] (Table 2, Figure 1). The prognostic significance of high Neo-fs index for
better OS (HR 0.349; p = 0.002], DSS (HR 0.349; p = 0.002], and RFS (HR 0.347; p = 0.009]
was retained in the AAA-recipient subgroup (Table S1).
In multivariate analysis, high Neo-fs index (>4) was an independent prognostic factor
for favorable OS (HR 0.595; p= 0.030), DSS (HR 0.430; p= 0.011), and RFS (HR 0.481;
p = 0.020) (Table 3). The independent prognostic significance was retained for OS (HR 0.314;
p = 0.003) and DSS (HR 0.372; p = 0.003) in the AAA-recipient subgroup (Table S2).
We analyzed the clinicopathological characteristics of clear cell RCC patients based on
the Neo-fs index (Table S3). Higher Neo-fs index was associated with International Society
of Urological Pathology (ISUP) grade 1–2 (p < 0.001), pN0/pNx (p < 0.001), clear resection
margin (p = 0.033), no AAA treatment (p = 0.009), and no mTOR inhibitor treatment
(p = 0.016), although there was no difference with respect to sex, age, procedure, tumor size,
pT stage, lymphovascular invasion, necrosis, or sarcomatoid change based on the Neo-fs
index (Table S3).




Figure 1. Kaplan‒Meier survival curves for patients with clear cell renal cell carcinoma based on the immunohistochem-
istry-based Neo-fs index. Neo-fs index—the number of highly expressed protein markers among APC, NOTCH1, 
ARID1A, EYS, and filamin A—demonstrated a cumulative favorable effect on overall survival (OS) (p < 0.001) (a), disease-




p <0.001 p <0.001
p <0.001p = 0.018
p <0.001 p = 0.008
Figure 1. Kaplan-Meier survival curves for patients with clear cell renal cell carcinoma based on the immunohistochemistry-
based Neo-fs index. Neo-fs index—the number of highly expressed protein markers among APC, NOTCH1, ARID1A, EYS,
and filamin A—demonstrated a cumulative favorable effect on overall survival (OS) (p < 0.001) (a), disease-specific survival
(DSS) (p < 0.001) (b), and recurrence-free survival (RFS) (p = 0.018) (c) in patients with clear cell renal cell carcinoma. When
stratified into Neo-fs index >4 and ≤4, Neo-fs index >4 was associated with favorable OS (p < 0.001) (d), DSS (p < 0.001) (e),
and RFS (p = 0.008) (f).
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2.5. Impact of Immunohistochemical Markers and Neo-fs Index on the Treatment Response
We analyzed the response to AAA and mTOR inhibitor, or lack thereof, with respect
to the five individual independent prognosticators as well as the Neo-fs index (Table 4).
Low expression of APC (overall response rate (ORR) 32.1% vs. 0%; p = 0.092), EYS (ORR
34.1% vs. 11.8%; p = 0.114), and Filamin A (ORR 33.3% vs. 7.7%; p = 0.088) exhibited a
tendency for a better response to AAA. We also observed a cumulative effect of the five
markers on the response to AAA; higher Neo-fs index values (increased in a stepwise
manner) conferred an improved AAA response (p = 0.027). We discovered that patients
with a high Neo-fs index (>4) (ORR 44.4%) exhibited significantly higher ORR to AAA than
those with a low Neo-fs index (≤4) (ORR 14.7%) (p = 0.010). With respect to the mTOR
inhibitor, low EYS expression exhibited a tendency for a better response to mTOR inhibitor
(disease control rate (DCR) 38.1% vs. 0%; p = 0.075), while other markers failed to predict
the response to mTOR inhibitor.
Table 4. Association between immunohistochemical expression and the response to therapy.
Variables Anti-Angiogenic Agent mTOR Inhibitor
PR/SD,PD ORR p SD/PD DCR p
Low APC 17/36 32.1%
0.092
7/18 28.0%
0.999High APC 0/8 0% 1/2 33.3%
Low NOTCH1 12/26 31.6%
0.406
5/14 26.3%
0.573High NOTCH1 5/18 21.7% 3/6 33.3%
Low ARID1A 17/44 27.9%
0.999
8/19 29.6%
0.999High ARID1A 0/1 0% 0/1 0.0%
Low EYS 15/29 34.1%
0.114
8/13 38.1%
0.075High EYS 2/15 11.8% 0/7 0%
Low Filamin A 16/32 33.3%
0.088
6/16 27.3%
0.999High Filamin A 1/12 7.7% 2/4 33.3%





2 1/4 20.0% 0/1 0%
3 1/8 11.1% 2/1 66.7%
4 3/14 17.6% 2/6 25.0%
5 12/15 44.4% 4/10 28.6%
Indel signatures (positive number)
Neo-fs index ≤ 4 5/29 14.7%
0.010
4/10 28.6%
0.999Neo-fs index > 4 12/15 44.4% 4/10 28.6%
ORR: Overall response rate (CR + PR/all evaluable patients); DCR: Disease control rate (CR + PR + SD/all
evaluable patients); mTOR inhibitor, mammalian target of rapamycin (mTOR) inhibitor.
2.6. The Cancer Genome Atlas (TCGA) Gene Expression
To evaluate the association between immune gene signature [8] and the genes of
corresponding proteins, which showed independent prognostic significance, we evaluated
the mRNA expression of 510 clear cell RCC patients using the available RNA seq data in the
TCGA PanCancer Atlas dataset. Neo-fs index, initially developed using protein markers,
was used to identify correlations with the RNAseq data. The Neo-fs index was evaluated as
the number of genes with low expression among the five genes (APC, NOTCH1, ARID1A,
EYS, and FLNA). The mean z-scores of each immune gene signature with respect to the
Neo-fs index are illustrated in Figure 2. The mean value was compared between patients
with a low Neo-fs index (0–1) and a high Neo-fs index (4–5) (Table S4). High Neo-fs index
was associated with overexpression of immune gene signatures related to MHC class I
(p < 0.001), CD8+ T cell (p = 0.008), cytolytic activity (p = 0.002), and plasmacytoid dendritic
cells (p = 0.041), as compared with low Neo-fs index (Figure 2, Table S4). Immune gene
signatures related to APC co-stimulation and T cell co-inhibition and were slightly enriched
in high Neo-fs index but were not significant (p = 0.305 and 0.705 respectively) (Figure 2,
Table S4). In contrast, a high Neo-fs index was associated with decreased expression of
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immune gene signatures associated with APC co-inhibition (p = 0.011) and type II-IFN
response (p < 0.001) (Figure 2, Table S4).
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2.7. Molecular Phenotype of Clear Cell Renal Cell Carcinoma and Neo-fs Index
We have identified a total of 49 genes harboring somatic mutations in 12 cases of clear
cell RCC by targeted next-generation sequencing (NGS) (Figure 3). The most frequently
mutated gene was VHL (10 cases, 83.3%), followed by BAP1 (six cases, 50.0%). The genes
harboring frameshift insertion were VHL, PBRM1, CSF1R, and ABCC5, and the genes
harboring frameshift deletion were VHL, BAP1, TSC2, PBRM1, ALK, ERRFI1, and COBLL1.
The mean total mutation count was 6.67 ± 3.53. SNV counts (5.17 ± 2.89) were about
four times higher than the total indel count (1.33 ± 1.56) (Table S5). The mean frameshift
indel count was 1.08 ± 1.08 (Table S5). Eight cases with high Neo-fs index ( > 4) showed a
higher count of total mutation (8.63 ± 1.85) and SNV (6.63 ± 2.00) compared with those
in four cases with low Neo-fs index (0–2) (total mutation, 2.75 ± 2.63; SNV, 2.25 ± 2.06)
(p = 0.001 and p = 0.005, respectively) (Table S5). Cases with high Neo-fs index (>4) also
demonstrated a higher total indel count (1.88 ± 1.64) than those with low Neo-fs index
(0–2) (0.25 ± 0.50) (p = 0.030), although only a weak tendency was observed regarding
frameshift indel count (high Neo-fs index, 1.38 ± 1.19; low Neo-fs index, 0.50 ± 0.58)
without statistical significance (p = 0.201) (Table S5).
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3. Discussion
In this study, we investigated the prognostic value of individual protein markers—
whose genes produce numerous frameshift neoantigens—and revealed that five protein
markers (APC, NOTCH1, ARID1A, EYS, and filamin A) were independently associated
with adverse prognosis when highly expressed in clear cell RCC tissues. Although EYS
has not previously been investigated in the context of prognosis, the adverse prognostic
impact of APC, NOTCH1, ARID1A, and filamin A has been reported in other cancer types.
The expression of APC is associated with poor survival in pancreatic ductal adenocarci-
noma [9]. NOTCH1 expression is associated with poor survival as well as advanced grade
or TNM stage in hepatocellular carcinoma (HCC) and colorectal cancer [10]. In clear cell
RCC, NOTCH1 expression is associated with advanced TNM stage and higher Fuhrman
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grade [11]. ARID1A loss—correlated with microsatellite instability and increased mutation
burden across cancer types [12]—has shown favorable prognostic impact—is known to
be associated with peritumoral lymphoid aggregates/tumor-infiltrating lymphocytes—in
esophageal adenocarcinoma, suggesting the impact of neoantigen-induced immunogenic-
ity on survival [13]. Filamin A expression has been reported to predict early recurrence
as well as advanced T stage and grade in HCC [14]. Filamin A expression is also asso-
ciated with shorter survival and early recurrence—as well as advanced TNM stage—in
NSCLC [15].
With the incorporation of the independent prognosticators, we have developed a
prognostic biomarker, named ‘Neo-fs index’, and revealed that a high Neo-fs index is
independently associated with a decreased risk of adverse events. We are the first to
demonstrate the prognostic value of the proteins—coded by genes producing numerous
frameshift neoantigens [1]—as individual markers, as well as an integrated index. Pre-
viously, a high frameshift indel load and high clonal neoantigen burden [16] have been
shown to be correlated with improved survival in NSCLC [1], although not for general
prognostic impact in RCC.
We have also demonstrated a predictive value of Neo-fs index for the response to AAA
in clear cell RCC in addition to the prognostic value. There was a gradual improvement
in the AAA response according to the increasing Neo-fs index. Improved response to
AAA was also achieved with low expression of APC, EYS, and filamin A as individual
markers. A recent study has evaluated the clinical outcome of frameshift indel count in
RCC, but the prognostic significance of frameshift indel count has not been demonstrated
in AAA- recipients [17,18]. In contrast, we have demonstrated that a higher Neo-fs index,
a marker which is based on the recurrent genes producing frameshift indel neoantigens,
was associated with favorable OS and DSS in AAA-recipients, in addition to its predictive
value for better AAA response.
To investigate the reason for favorable prognosis and better AAA response in cases
with a higher Neo-fs index, we have analyzed the association between Neo-fs index and
immune gene signature. Previously, a bi-directional link between angiogenesis and the
immune system has been demonstrated. AAAs enhance the infiltration and function of
effector T cells and diminish the infiltration and activity of immunosuppressive cells such
as regulatory T cells and myeloid-derived suppressor cells (MDSCs) [19,20]. Also, MDSCs,
activated by type II-IFN response, promote neo-angiogenesis and secrete angiogenetic
factors, resulting in resistance to AAAs [21–24]. High Neo-fs index samples were enriched
for genes linked to immune activation-associated signatures (e.g., plasmacytoid dendritic
cells, cytolytic activity, MHC class I, and CD8+ T cell) had a reduced the gene signatures
related to immune suppression such as type II-IFN response, which might have affected
the response to AAA as well as favorable survival in general.
Moreover, we have evaluated the mutational landscape according to the Neo-fs index
utilizing targeted NGS. Patients with a high Neo-fs index harbored higher counts of total
mutation, SNV, and total indel than those with a low Neo-fs index. Although frameshift
indel count was not significantly different between the two groups, the favorable prognosis,
as well as enhanced T cell infiltration and function in the patients with high Neo-fs index,
could be explained by higher SNV and total indel count because non-synonymous SNVs.
are able to generate neoantigens that facilitate the generation of the T cell response [25–27].
In addition, a recent study in RCC patients has shown that SNVs. and in-frame indels
generate neopeptides, and SNVs. produce as many immunogenic neoepitopes as frameshift
indels, although neopeptides arising from frameshift indels showed less similarity to wild-
type than those from SNVs. [28].
Interestingly, SNV was the most frequent mutation type in this study, although clear
cell RCC is known to harbor the highest proportion of coding indels with low non-
synonymous SNV burden [1]. However, Hansen et al. [28] has also shown that SNVs.
accounted for the largest proportion of mutations leading to a greater number of pre-
dicted neopeptides.
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Although genetic biomarkers (e.g., loss-of-function mutation of VHL) and molec-
ular sub-classifications (e.g., ccrcc2/ccrcc3 from unsupervised transcriptome analysis)
have shown their value in predicting better response to AAAs, none of the genetic or
molecular biomarkers are in clinical practice [29]. On the other hand, histology-based
biomarkers are more applicable for routine clinical use in terms of low time-consumption,
cost-effectiveness, and ease of standardization regarding methodology and interpretation;
nevertheless, there are scant histology-based biomarkers to predict response to AAAs in
RCC [29]. Here we have revealed the predictive value of a novel histology-based marker,
Neo-fs index, in clear cell RCC patients, which might address longstanding unmet needs
for practical biomarkers reflecting tumor biology to guide the selection of patients sensitive
to AAAs.
A limitation to this study is its single institutional design with retrospective nature.
However, we analyzed a large series of cases with an adequate median follow-up duration
and developed a simple and easily applicable protein-based biomarker—Neo-fs index—in
clear cell RCC as a significant prognostic marker as well as a predictive marker for the
response to AAA. Another limitation to this study is that we did not found a significant
difference in frameshift indel burden according to Neo-fs index, probably due to the
limitation inherent to the targeted sequencing compared with whole-genome sequencing.
However, we have observed a weak tendency for higher frameshift indel count as well as
significantly higher total mutation count, SNV count, and total indel count.
4. Materials and Methods
4.1. Case Selection
We selected 745 patients with clear cell RCC who had been treated at the Asan Medical
Center between July 2011 and December 2013 based on our pathology records. Patients
without available tissue or available clinical data were excluded (n = 107). Finally, a total
of 638 patients who underwent partial nephrectomy (n = 340) or radical nephrectomy
(n = 298) were selected for subsequent analysis. Electronic medical records were retrieved
to obtain clinical data, including age, sex, surgical procedure, adjuvant therapy regimen,
treatment response, distant metastasis, and survival outcomes. For targeted NGS, we
selected separate 25 cases with clear cell RCC, for which the targeted NGS was performed
between 2019 and 2020, and immunohistochemistry was available in the same paraffin
block as NGS. This study was approved by our Institutional Review Board (approval
number, 2019-0753).
4.2. Pathological Evaluation
Data retrieved from pathological reports included primary diagnosis, tumor size,
nuclear grade, resection margin status, lymphovascular invasion, necrosis, sarcomatoid
change, and pathological TNM stage, including the extent of the primary tumor, nodal,
and distant metastasis. The nuclear grade was evaluated in accordance with the grading
system recommended by the WHO/ISUP [2]. The pathological TNM stage was eval-
uated in accordance with the guidelines provided in the AJCC cancer staging manual
(8th edition) [30].
4.3. Immunohistochemistry
Immunohistochemistry was performed for APC, NOTCH1, ARID1A, FAT1, VHL,
EYS, KMT2D, Filamin A, PTEN, and p53 on 4-µm-thick serial sections of tissue microarray
(TMA) paraffin blocks containing two 3-mm-diameter cores per sample. Tissues were
deparaffinized at 76 ◦C for 4 min and rehydrated in a graded ethanol series. After blocking
the endogenous peroxidase by incubating the sections with the OV PEROX inhibitor at
37 ◦C for 4 min, the sections were incubated for 16 min at 37 ◦C with the following primary
antibodies: anti-APC antibody (rabbit, 1:50; GTX16794, Clone CC1; Genetex, Irvine, CA,
USA), anti-Notch1 antibody (mouse, 1:200; ab52627, Clone EP1238Y; Abcam, Cambridge,
UK), anti-ARID1A antibody (rabbit, 1:100; clone HPA005456; Sigma-Aldrich, Darmstadt,
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Germany), anti-FAT1 antibody (rabbit, 1:100; NBP1-84565; Novus Biologicals, Littleton, CO,
USA), anti-VHL antibody (mouse, 1:2000; ab140989, clone OTI1E1; Abcam), anti-EYS/RP25
antibody (rabbit, 1:100; NBP1-90038; Novus Biologicals), anti-KMT2D antibody (rabbit,
1:100; NBP1-89123; Novus Biologicals), anti-filamin A antibody (mouse, 1:400; ab76289,
clone EP1238Y; Abcam), anti-PTEN antibody (rabbit, 1:100; 138G6; Cell Signaling, Dan-
vers, MA, USA), and anti-p53 antibody (mouse, 1:1000; DO-7; Dako, Glostrup, Denmark).
Then, heat-induced antigen retrieval was performed. A Benchmark XT automatic staining
system (Ventana Medical Systems, Tucson, AZ, USA) was utilized for the staining pro-
cedure, and reactions were visualized using OptiView DAB IHC Detection Kit (Ventana
Medical Systems, Tucson, AZ, USA) and light counterstaining with hematoxylin. Lastly,
the sections were dehydrated in ethanol and cleared in xylene. KMT2C, MAP2K1, and
VPS13C were excluded from the evaluation because the expression level of these proteins
as—identified by immunohistochemistry on formalin-fixed tissues—was not suitable for
evaluation. When tumor cells were lost during the serial sectioning of the TMA paraffin
blocks for immunohistochemistry or when there were no remaining samples to test the
expression of some markers, the markers were analyzed in the order of priority using the
cells as available.
Immunostaining of all markers was scored as negative (0), weak (1+), moderate (2+),
and strong (3+) by two independent pathologists (JK and HG) who were blinded to the
clinicopathological information. The expression of APC, NOTCH1, FAT1, EYS, filamin A,
and PTEN was evaluated in the cytoplasm and the expression of ARID1A, VHL, KMT2D,
and p53 was evaluated in the nucleus. Then the expression of each marker was stratified
into low (0 for VHL, PTEN, and p53; 0–1 for APC, NOTCH1, FAT1, EYS, and KMT2D;
0–2 for ARIDA1, and Filamin A) or high (1–3 for VHL, PTEN, and p53; 2–3 for APC,
NOTCH1, FAT1, EYS, and KMT2D; 3 for ARID1A, and filamin A) expression, respectively.
Representative images of each marker are illustrated in Figure S1.
4.4. Outcome Measures
The primary endpoints were OS, DSS, RFS, and ORR to AAA and mTOR inhibitor.
OS was defined as the duration from surgery until death from any cause or last follow-up.
DSS was defined as the duration from surgery until death due to clear cell RCC or until
the date of the last follow-up or death from any other causes. RFS was defined as the
duration from surgery until the date of the first locoregional or distant relapse or until the
last follow-up date. Patients with synchronous distant metastasis (n = 38) were excluded
from RFS analysis. The ORR was defined as the percentage of patients with complete
response (CR) or partial response (PR) out of all evaluable patients according to RECIST 1.1
criteria [8]. When ORR could not be evaluated, DCR, defined as the percentage of patients
with CR, PR, or stable disease (SD) out of all evaluable patients, was evaluated instead [31].
4.5. TCGA Gene Expression Data
To evaluate the association between gene expression and immune signature, we
retrieved RNA Seq V2 RSEM data (mRNA expression z-scores relative to diploid samples)
from the Kidney Renal Cell Carcinoma (TCGA, PanCancer Atlas) dataset, available at
cBioPortal for Cancer Genomics (https://www.cbioportal.org/, accessed on 25 October
2020). The gene sets used to define immune gene signature were adopted from Rooney
and colleagues [8]. The mRNA expression of each gene was stratified into low or high
expression by the median value.
4.6. Targeted Next-Generation Sequencing
After determining tumor purity by review of matched hematoxylin and eosin (H&E)
slides, genomic DNA (gDNA) was extracted from 2–5 sections (6 µm thick) of paraffin
blocks in the marked area. Following de-paraffinization by treatment with xylene and
ethanol, gDNA was isolated with the utilization of NEXprep FFPE Tissue kit (#NexK-
9000; Geneslabs, Seongnam, Korea), in compliance with the manufacturer’s protocol [31].
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Quantification of DNA was performed with the utilization of Qubit™ dsDNA HS Assay
kit (Thermo Fisher Scientific, Waltham, MA, USA).
Targeted NGS was performed using the MiSeq platform (Illumina, San Diego, CA,
USA) with OncoPanel AMC version 4.3 (OP_AMCv4.3) designed in-house by ASAN Center
for Cancer Genome Discovery (ASAN-CCGD) to target a total of 328 genes (808 kb), includ-
ing complete exonic sequence of 225 genes, 105 hot spots, and partial intronic sequence of
six genes (Table S6) [31]. A DNA library was prepared by fragmentation of gDNA (200 ng)
to an average of 250 bp by S1 enzyme (S1 method) [32], followed by sequential reactions
of end repair, A tailing, and ligation of 50 ng of purified DNA with a TruSeq adaptor, by
the utilization of a SureSelectXT Reagent kit (Agilent Technologies, Santa Clara, CA, USA).
Each library was addressed with sample-specific barcodes (6 bp) and quantified using the
Qubit kit. Eight libraries were pooled to yield a total of 750 ng for hybrid capture using
an Agilent SureSelectXT custom kit (OP_AMCv3 RNA bait; Agilent Technologies). The
concentration of enriched target was measured by quantitative polymerase chain reaction
(qPCR; Kapa Biosystems, Woburn, MA, USA), and the DNA libraries which passed quality
checks were loaded onto the MiSeq for paired-end sequencing.
Sequencing reads were aligned to the human reference genome (National Center for
Biotechnology Information build 37) with the Burrows-Wheeler Aligner (0.5.9) with the
default options [33]. PCR duplicates were removed using MarkDuplicates in the Picard
package (Broad Institute, Cambridge, MA; available at http://broadinstitute.github.io/
picard, accessed on 25 October 2020). De-duplicated reads were re-aligned at known
indel positions using GATK IndelRealigner tool [34], followed by re-calibration of base
qualities using GATK TableRecalibration tool. Somatic variant calling for SNVs. and
short indels were performed with unmatched normal using the Mutect (version 1.1.7)
and the SomaticIndelocator tool in GATK (Broad Institute) [34–36]. Common germline
variants from the somatic variant candidate were filtered out using the Single Nucleotide
Polymorphism database (dbSNP, build 141; found in >1% of samples), Exome Aggregation
Consortium release 0.31 (threshold frequency 0.001), Korean Reference Genome database
(KRGDB), and an in-house panel of normal variants [37,38]. Final somatic variants were
annotated using the Variant Effect Predictor version 79 [39], which were then converted to
maf file format by vcf2maf (version 1.6.12; available at https://github.com/mskcc/vcf2maf,
accessed on 25 October 2020). False-positive variants were manually curated with the
utilization of Integrative Genomics Viewer (version 2.4) [40].
Of the 25 cases enrolled for targeted NGS, cases with the lowest Neo-fs index available
(2; four cases) and the highest Neo-fs index (5; eight cases) were selected for further
evaluation to compare the mutational spectrum according to the Neo-fs index.
4.7. Statistical Analysis
For descriptive variables, mean and standard deviation or median with range were
utilized for continuous variables, and number and relative frequency were utilized for
categorical variables. The means were compared using an independent two-sample t-test,
and the frequencies were compared using chi-square or Fisher’s exact test. A univariate
Cox proportional hazards regression analysis was conducted to identify the prognostically
significant clinicopathological factors and immunohistochemical markers. A multivariate
Cox proportional hazards regression was conducted to identify independent predictors
of outcomes. For survival analysis, Kaplan-Meier curves were also generated and were
compared using the Log-rank test. The results are presented as HRs with a 95% con-
fidence interval. All statistical analyses were performed using SPSS version 21.0 (IBM
Corp, Armonk, NY, USA). All p-values presented are two-tailed, and p-values < 0.05 were
considered significant.
5. Conclusions
In summary, we have introduced a novel prognostic and predictive biomarker—
Neo-fs index—in clear cell RCC reflecting immune gene signatures as well as SNV and
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indel counts. Specifically, patients with a high Neo-fs index exhibited better survival and
favorable response to AAA. The practical utilization of the Neo-fs index may pave the way
for better-personalized care in patients with clear cell RCC.
Supplementary Materials: The following are available online at https://www.mdpi.com/2072-6
694/13/6/1199/s1, Figure S1: Representative images depicting high and low expression of APC,
NOTCH1, ARID1A, FAT1, VHL, EYS, KMT2D, Filamin A, PTEN, and p53 in clear cell renal cell carci-
noma; Table S1: Univariate analysis to identify a correlation between survival and clinicopathological
factors and immunohistochemical results in patients receiving anti-angiogenic therapies; Table S2:
Multivariate analysis to identify a correlation between survival and clinicopathological factors and
immunohistochemical results in patients receiving anti-angiogenic therapies; Table S3: Clinicopatho-
logical characteristics of the study population based on the Neo-fs index; Table S4: Immune signature
(mean z-scores) in clear cell renal cell carcinoma based on the Neo-fs index; Table S5: Comparison of
mutational landscape in clear cell renal cell carcinoma based on Neo-fs index; Table S6. The list of
genes targeting in the OncoPanel AMC version 4.3.
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